JP2018526443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526443A5 JP2018526443A5 JP2018530651A JP2018530651A JP2018526443A5 JP 2018526443 A5 JP2018526443 A5 JP 2018526443A5 JP 2018530651 A JP2018530651 A JP 2018530651A JP 2018530651 A JP2018530651 A JP 2018530651A JP 2018526443 A5 JP2018526443 A5 JP 2018526443A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- lgals3bp
- pharmaceutical composition
- amount
- nephritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212163P | 2015-08-31 | 2015-08-31 | |
| US62/212,163 | 2015-08-31 | ||
| PCT/US2016/049378 WO2017040464A1 (en) | 2015-08-31 | 2016-08-30 | Methods for the modulation of lgals3bp to treat systemic lupus erythematosus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199985A Division JP2021050217A (ja) | 2015-08-31 | 2020-12-02 | 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526443A JP2018526443A (ja) | 2018-09-13 |
| JP2018526443A5 true JP2018526443A5 (enExample) | 2019-08-15 |
Family
ID=56883878
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530651A Pending JP2018526443A (ja) | 2015-08-31 | 2016-08-30 | 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 |
| JP2020199985A Pending JP2021050217A (ja) | 2015-08-31 | 2020-12-02 | 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199985A Pending JP2021050217A (ja) | 2015-08-31 | 2020-12-02 | 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180251559A1 (enExample) |
| EP (1) | EP3344283A1 (enExample) |
| JP (2) | JP2018526443A (enExample) |
| CN (1) | CN107921112A (enExample) |
| AU (1) | AU2016317768A1 (enExample) |
| CA (1) | CA2994180A1 (enExample) |
| HK (1) | HK1252815A1 (enExample) |
| IL (1) | IL257755A (enExample) |
| WO (1) | WO2017040464A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018156448A1 (en) * | 2017-02-21 | 2018-08-30 | The Board Of Regents Of The Uiversity Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| KR101946884B1 (ko) * | 2017-04-25 | 2019-02-13 | 고려대학교 산학협력단 | 대사체 분석을 이용한 베체트병의 진단방법 |
| EP4174086A4 (en) * | 2020-06-30 | 2024-07-24 | The Asan Foundation | ANTIBODIES SPECIFICALLY BINDING TO LGALS3BP AND USE THEREOF |
| KR102704018B1 (ko) * | 2020-06-30 | 2024-09-06 | 재단법인 아산사회복지재단 | Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도 |
| KR20230160803A (ko) | 2021-03-24 | 2023-11-24 | 에이지씨 가부시키가이샤 | 축전 디바이스 전극용 프라이머, 프라이머층 형성용의 조성물, 축전 디바이스용 전극 및 이차 전지 |
| WO2025075163A1 (ja) * | 2023-10-04 | 2025-04-10 | 国立大学法人東北大学 | 自己反応性ｄｎ２ｂ細胞が産生する自己抗体およびその使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200001247T2 (tr) * | 1997-01-10 | 2002-06-21 | Biogen Inc. | Anti-CD40L bileşikleri ile lupus nefritis tedavisi. |
| CA2470763A1 (en) * | 2001-12-18 | 2003-06-26 | Mondobiotech Laboratories Anstalt | Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases |
| US8163896B1 (en) * | 2002-11-14 | 2012-04-24 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| ES2244270A1 (es) * | 2003-01-31 | 2005-12-01 | Pilar Universidad Autonoma De Madrid | Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69. |
| WO2004076682A2 (en) * | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| EP2566878A4 (en) * | 2010-03-26 | 2013-10-23 | Jolla Inst Allergy Immunolog | METHOD OF INHIBITING INFLAMMATORY AND INFLAMMATORY DISEASES BY GAL-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN) |
| JP2013527834A (ja) * | 2010-03-29 | 2013-07-04 | マサチューセッツ インスティテュート オブ テクノロジー | 抗炎症因子 |
| EP2646826A1 (en) * | 2010-11-30 | 2013-10-09 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patienten Zorg | Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle |
-
2016
- 2016-08-30 WO PCT/US2016/049378 patent/WO2017040464A1/en not_active Ceased
- 2016-08-30 AU AU2016317768A patent/AU2016317768A1/en not_active Abandoned
- 2016-08-30 JP JP2018530651A patent/JP2018526443A/ja active Pending
- 2016-08-30 US US15/755,692 patent/US20180251559A1/en not_active Abandoned
- 2016-08-30 EP EP16762946.8A patent/EP3344283A1/en not_active Ceased
- 2016-08-30 CN CN201680050415.7A patent/CN107921112A/zh active Pending
- 2016-08-30 HK HK18112121.7A patent/HK1252815A1/zh unknown
- 2016-08-30 CA CA2994180A patent/CA2994180A1/en not_active Abandoned
-
2018
- 2018-02-27 IL IL257755A patent/IL257755A/en unknown
-
2020
- 2020-12-02 JP JP2020199985A patent/JP2021050217A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526443A5 (enExample) | ||
| Marrani et al. | How should we classify Kawasaki disease? | |
| Rosenblad et al. | Eculizumab treatment for rescue of renal function in IgA nephropathy | |
| Campo et al. | Pulmonary alveolar proteinosis: diagnostic and therapeutic challenges | |
| JP2017079785A5 (enExample) | ||
| JP2014012726A5 (enExample) | ||
| JP2011184466A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| Faz-Munoz et al. | ANCA-associated vasculitis and IgG4-related disease overlap syndrome: a case report and literature review | |
| JP2013521303A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| JP2016512817A5 (enExample) | ||
| Haris et al. | Clinical outcomes of ANCA-associated vasculitis in elderly patients | |
| JP2020506162A5 (enExample) | ||
| JP2021504321A5 (enExample) | ||
| Goodson et al. | Rheumatoid factor, smoking, and disease severity: associations with mortality in rheumatoid arthritis | |
| JP2015511588A5 (enExample) | ||
| Abril | Churg-strauss syndrome: an update | |
| Kalyoncu et al. | Henoch-Schönlein purpura: a case with atypical presentation | |
| Canas-Ventura et al. | Tocilizumab in amyloidosis-associated kidney disease secondary to inflammatory bowel diseases | |
| Kaneko et al. | Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis | |
| RU2019101210A (ru) | Производное оксазина для применения в предупреждении болезни альцгеймера у пациентов, находящихся в группе риска | |
| Kher | Acute glomerular diseases in Children | |
| Carrión-Barberà et al. | Safe and successful treatment of refractory polyarteritis nodosa with tocilizumab in a patient with past hepatitis B virus infection: a case-based review | |
| Leeaphorn et al. | Idiopathic granulomatous interstitial nephritis responsive to mycophenolate mofetil therapy |